Researchers reported encouraging results from the BEGONIA Trial, which tested a combination of the antibody-drug conjugate Dato-DXd and the immunotherapy Durvalumab in patients with metastatic triple-negative breast cancer (TNBC). The treatment showed high effectiveness, with nearly 80% of patients experiencing tumor shrinkage. Objective response rates were 79% in one group and 81.8% in another, and some patients achieved complete responses. Median progression-free survival was 14 months in one arm, with the other arm not yet reached, indicating durable benefit.
Side effects were common but manageable, including mouth sores, nausea, hair loss, constipation, and fatigue. Only a small percentage of patients stopped treatment due to side effects, and serious adverse events occurred in a minority of patients. The trial included a high-risk group, with over 60% having cancer spread to internal organs and many having prior treatments for early-stage cancer.
Overall, the combination of Dato-DXd and durvalumab shows strong promise as a powerful treatment option for metastatic TNBC, offering both high response rates and lasting benefits with an acceptable safety profile.